

# PharmaGuide

The Desktop App for INSTANT reference on available medicines



## MANUAL

Desktop App	(Page)
• How to Install on a Computer	3-8
• How to Subscribe to the PharmaGuide Desktop App	9-13
• Manual for Downloading Complete Data or Renewing Subscription for the PharmaGuide Desktop App	14-17
• Contents of the PharmaGuide Desktop App and How to use the PharmaGuide Desktop App	18-27
• FAQ (Frequently Asked Questions)	28-30
• PharmaGuide Editorial Policy, Source of Information and Liability of Information	31-32

[www.epharmaguide.com](http://www.epharmaguide.com)  
email: [info@epharmaguide.com](mailto:info@epharmaguide.com)

Welcome to the **PharmaGuide** Desktop App, a medical reference tool that contains comprehensive prescribing and trade information for all medicines available in the country.

This is an offline application, which means you can have the most critical information on all medicines at your fingertips.

This installation guide will explain how to download the **PharmaGuide** Desktop App with complete data onto your computer.

After installation, please refer to the User Manual. It provides a detailed explanation of the features and contents of the **PharmaGuide** Desktop App, helping you better understand the application and utilize it to its fullest potential.

IMPORTANT: Always fill out the subscription form with accurate information. This will ensure that you can receive the **PharmaGuide** Desktop App for free in case your computer is lost. Providing CORRECT information enables us to verify your personal details. Once the verification process is complete, you will be able to download the application free of cost.

[www.epharmaguide.com](http://www.epharmaguide.com)  
email: [info@epharmaguide.com](mailto:info@epharmaguide.com)




## How to Install on a Computer



Directions for users who are downloading the **PharmaGuide** Desktop Application for the first time.


## Step 1

Open your web browser and go to our website at [www.epharmaguide.com](http://www.epharmaguide.com).



## Step 2

Click on the "Products" tab, then select "PharmaGuide Desktop" and click on "Download".




### Step 3

Once the download is complete, navigate to the downloaded file named **PharmaGuide.exe** and double-click on it to start the installation process.


### Step 4

Follow the InstallShield Wizard to install the application. Click "**Next**" to proceed with the installation process.




### Step 5

The next screen will prompt you to choose the destination folder where the application will be installed. By default, a recommended folder will be pre-selected, but you can change it if desired. Click "**Next**" to continue with the installation.




**Step 6**

Click "**Install**" to start installing the application.




## Step 7

The installation process will commence, and you will see a progress bar indicating the status of the installation. Please note that this may take some time.




**Step 8**

Once the installation is complete, you will see a message confirming the successful installation. Click "**Finish**" or "**Close**" to exit the InstallShield Wizard.



After the installation, a shortcut icon will be created on your desktop.





## How to subscribe to the PharmaGuide Desktop App



Directions for users who are using the **PharmaGuide** Desktop app and want to subscribe to the data.

## Step 1


Open the *PharmaGuide* application from your desktop.



## Step 2

Enter your email address. Please make sure to enter the correct email address, as the application is associated with your email for the subscription. A verification link will be sent to your email for email address verification.


- Enter your email address.
- Click to **"I Agree to the Terms of Services"**.
- Now click **"Continue"**.



### Step 3

Please check the email address you entered earlier in the **PharmaGuide** application. Verify your email address by clicking on the verification link that has been sent to your email.


**Note:** Don't forget to check your junk mail or spam folder if the verification email is not received in your inbox.



Information for better care

### Step 4

Click "**Continue**" to proceed.



## Step 5

Fill in the required form and click "Continue."


The screenshot shows a web browser window with the PharmaGuide logo in the top left. The page is divided into three vertical sections. The left section contains a 'Log In' link, the email 'epharmaguide@gmail.com', a checkbox for 'I agree to the Terms of Service', a 'Continue' button, and a 'Connect to local server' link. The middle section is titled 'PharmaGuide Personal Information' and contains form fields for 'First Name', 'Last Name', 'Phone Number', and 'Profession\*'. Below these fields are 'Continue' and 'Back' buttons. The right section features a large red PharmaGuide logo on a light pink geometric background.

## Step 6

Enter the 14-digit subscription code and click "Continue."

The screenshot shows the same PharmaGuide web browser window, but the middle section is now titled 'PharmaGuide Subscription'. It contains a '14-digit Subscription Code' input field and 'Continue', 'Skip', and 'Back' buttons. The left and right sections remain the same as in Step 5.

The following screen will appear, indicating that the application has been downloaded with complete data, and is now ready for use.



Your data will be automatically updated every month.

**Note:** An internet connection is required to update the app data.

**You can now use the *PharmaGuide* Desktop App anytime, anywhere.**




**Manual for Downloading Complete Data  
Or  
Renewing Subscription for the PharmaGuide  
Desktop App**



Directions for users who are using the **PharmaGuide** Desktop app with limited data OR who want to renew their subscription.

### Step 1


Double click **PharmaGuide** icon to open the application.



PharmaGuide


### Step 2

In order to access the complete data, you need to be connected to the internet. Click on the “**Settings**” option located on the top right corner of the application window.




### Step 3

Click on the “**Subscribe to Data**” button in the settings menu.




### Step 4

Enter the 14-digit subscription code provided to you and click on “**Submit.**”



Once you have entered the subscription code, the application will start downloading the complete data. A screen will appear indicating that the application has finished downloading the complete data and is now ready for use.



Your data is automatically updated every month, ensuring that you always have access to the latest medical information.

**Note:** An internet connection is required to update the app data.

Now you can use the *PharmaGuide* Desktop Application anytime, anywhere



## Contents of the PharmaGuide Desktop App & How to use the PharmaGuide Desktop App

After you have installed the application, refer to the user manual. It contains a detailed explanation of the features and contents of the **PharmaGuide** Desktop App. The manual will help you better understand the application so that you can utilize it to its full potential.

## Contents of the PharmaGuide Desktop Application

**PharmaGuide** Desktop App contains comprehensive prescribing and trade information for the medicines available in the country where the application is provided (e.g., UAE, Qatar, etc.). The app is automatically updated on a monthly basis at no extra cost. These updates include WHO/USFDA drug prescribing information updates, new product additions, and price changes. This ensures that healthcare professionals are always up to date with the latest information on the medicines available in their country.

### Prescribing information is provided in the following order in the PharmaGuide Desktop App:

- 1 **Name of the Product** (Brand & Generic)
- 2 **Company**
- 3 **Therapeutic Category:** displayed in black color below the product name.
- 4 **Drug Category:** indicated in golden color (e.g., Sulphonylurea)
- 5 **Generic Name/Contents:** shown in purple color under the drug category. For products with a large number of ingredients (e.g., Centrum), the complete formula of the product is provided.
- 6 **Dosage Form & Strength** of the relevant product.
- 7 **Pack Size & Retail Price** In the Country Edition, the currency name denotes the country of availability and price. For some products, prices may not be mentioned, and only the currency name indicates availability in that country.
- 8 **Brand Names of Generic:** Tap the "BRAND" button to see the list of brands available for the generic name.
- 9 **Risk Factor:** This section includes information on contraindications, precautions, and risks during pregnancy and lactation for the relevant product.
- 10 **Indications**
- 11 **Dosage**
- 12 **Advice to Patient**
- 13 **Administration:** For injectables, the method of preparation and administration is clearly described, including the diluent and its quantity.
- 14 **Unlicensed Use:** Indications and dosages mentioned may not be approved by the relevant Drug Regulatory Authority.
- 15 **Pharmacokinetics**
- 16 **Interactions**
- 17 **Adverse Effects**

## 18 Alternatives

Alternative products are displayed on the right side of the application.

Three features are provided for finding alternative products:

- Search for **Alternative product** with the SAME Content.
- Search for **Alternative product** in the SAME Drug Category.
- Search for **Alternative product** in the SAME Therapeutic Category.

For example, let's say you are searching for an alternative to Amaryl:

- Tap the content name, **Glimepiride**, to find other products that contain Glimepiride.
- Tap the drug category, **Sulphonylurea**, to find other products that belong to the same drug category.
- Tap the therapeutic category, **Hypoglycaemics**, to find other products that fall under the same therapeutic category.

The screenshot shows the PharmaGuide application interface. At the top, it says "PharmaGuide (Prescribing Information) - UAE". Below that is a search bar with "PharmaGuide Search here...". The main content area displays information for "Amaryl Sanofi-aventis".

**Hypoglycaemic excluding Insulin**  
**Sulphonylurea**  
**Glimepiride**  
Tab 1 mg: 2x15's: AED 25  
Tab 2 mg: 10's: -  
Tab 2 mg: 2x15's: AED 44.5  
Tab 3 mg: 10's: -  
Tab 3 mg: 2x15's: AED 62.5  
Tab 4 mg: 2x15's: AED 75

**Risk Factor**  
**Pregnancy:** Containdicated in pregnancy.  
**Lactation:** Containdicated or not recommended.  
**Contraindications:** Insulin-dependent (type 1) diabetes mellitus, diabetic ketoacidosis, diabetic precoma or coma, hypersensitivity to glimepiride or other sulphonylureas or sulfonamides, serious renal or hepatic dysfunction, dialysis patients.  
**Precautions:** Regular monitoring of glucose levels in blood and urine. Milder or absent symptoms of hypoglycaemia, e.g. in patients with autonomic neuropathy or taking beta blockers, clonidine, reserpine, guanethidine or other sympatholytic drugs. Temporary change over to insulin in exceptional stress situations (e.g. trauma, surgery, infections with fever). Mild to moderate renal or hepatic impairment, obesity, Adrenocortical insufficiency. Monitor hepatic and haematological function, Elderly.

**Indications**  
Non-insulin-dependent (type 2) diabetes mellitus.

**Dosage**  
**Adults:** Usual initial dosage 1 mg once daily; daily dosage may be increased at intervals of 1-2 wk and carried out stepwise as follow: 1 mg, 2 mg, 3 mg, 4 mg, 6mg and in exceptional cases 8 mg. Usual maintenance dose 1 mg to 4 mg daily.  
**Children:** Not recommended.

On the right side, there is a panel titled "Alternatives for Amaryl Sanofi-aventis". It lists several alternatives:

- Glimepiride
- Sulphonylurea
- Hypoglycaemic excluding Insulin

Below this list, it says "Filter brands here..". Then it says "Showing 22 alternatives for Amaryl with respect to Glimepiride,". The list of alternatives includes:

- Adglim Neobiocon
- Diameril Pharmalines
- Diapride Dar Al Dawa
- Econid Abbott
- Emipride Global Pharma
- G Pride Oman Pharma
- GLIMELIFE LIFEPHARMA
- Gedimadel Jedco
- Glide Deef

## Drug Interaction Checker

Click “Check Interactions” to go to drug interaction checker.

PharmaGuide (Prescribing Information) - Country

PharmaGuide Search here...

Go to interaction Checker Settings

Selected Drugs

Warfarin

Panadol CF gsk

Clear list [1] X [1] X

**Paracetamol**  
Panadol CF GSK

**Warfarin**

**Severity:** Moderate

**Effects:** Acetaminophen (APAP) appears to increase the antithrombotic effect of oral Anticoagulants in a dose-dependent manner. The interaction may not be clinically important with low-dose, infrequent use (no more than six 325 mg tablets/wk) of APAP. Delayed onset of action.

**Mechanism:** APAP or a metabolite causes possible enhancement in Vitamin K antagonism.

**Management:** Limit APAP use and Control coagulation parameters 1 to 2 times/wk when APAP is initiated or discontinued, particularly if more than 2,275 mg/wk is consumed. Be prepared to adjust the Anticoagulant dose as necessary.

**References**

1. Amato MG, Bussey H, Farnett T, Lyons R. Acetaminophen and risk factors for excess anticoagulation with warfarin. *JAMA* (1998) 280, 695-6.
2. Bell WR. Acetaminophen and warfarin: an undesirable synergy. *JAMA* (1998) 279, 702-3.
3. Gadisseur APA, van der Meer FJM, Rosendaal FR. Sustained intake of paracetamol (acetaminophen) during oral anticoagulant therapy with coumarins does not cause clinically important INR changes; a randomized double-blind clinical trial. *J Thromb Haemost* (2004) 3, 1464-8.
4. Gray CD. Acetaminophen and risk factors for excess anticoagulation with warfarin. *JAMA* (1998) 280, 655.
5. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. *JAMA* (1998) 279, 657-62.
6. Hylek EM. Acetaminophen and risk factors for excess anticoagulation with warfarin. *JAMA* (1998) 280, 697.
7. Lehmann DF. Enzymatic shunting: resolving the acetaminophen-warfarin controversy. *Pharmacotherapy* (2000) 20, 1464-8.
8. Mahe I, Bertrand N, Drouot L, Simoneau G, Mazoyer E, Bal dit Sollier C, Caulin C, Bergmann JF. Paracetamol: a haemorrhagic risk factor in patients on warfarin. *Br J Clin Pharmacol* (2005) 59, 371-4.
9. Riser J, Gilroy C, Hudson P, McCoy L, Willis TA. Acetaminophen and risk factors for excess anticoagulation with warfarin. *JAMA* (1998) 280, 696.

Check Interaction **BY BRAND** or **BY GENERIC** in your country

**Specimen of information when you search any Brand Name.** Scroll down the screen to see complete information.

---

**Amaryl** Sanofi Aventis

Hypoglycaemics excluding Insulins

Sulphonylurea

Glimepiride

Tab 1 mg; 2 mg; 3 mg; 4 mg.

**RISK FACTOR**

**Pregnancy:** Contraindicated in pregnancy.

**Lactation:** Contraindicated or not recommended.

**Indications:** Non-insulin-dependent (type 2) diabetes mellitus.

**Dosage: Adults:** Usual initial dosage 1 mg once daily; daily dosage may be increased at intervals of 1-2 wk and carried out stepwise as follows: 1 mg, 2 mg, 3 mg, 4 mg, 6 mg and in exceptional cases 8 mg. Usual maintenance dose 1 mg to 4 mg daily. **Children:** Not recommended.

**Advice to Patient: Take** just before meals or with first meal of the day.

**Do not** skip the meal after taking medication. **Contact** prescriber if there is severe or persistent hypoglycaemia, palpitations, sweaty palms, lightheadedness, extended vomiting or flu-like symptoms, skin rash, easy bruising or bleeding or change in color of urine or stool. **Do not** take other medication within 2 hours of taking glimepiride. Monitor glucose level as advised by the prescriber. **Carry** candy or other simple sugars to treat mild hypoglycaemia. **Carry** identification card indicating diabetes. **Avoid** direct sunlight, use protective clothing, wear sunscreen and eyewear to prevent photosensitivity. Avoid alcohol.

**Pharmacokinetics: Onset of action:** Peak effect: Blood glucose reductions: 2-3 hrs.

**Duration:** 24 hrs.

**Absorption:** 100%.

**Metabolism:** Hepatic.

**Half-life elimination:** 5-9 hrs.

**Time to peak, plasma:** 2-3 hrs.

**Excretion:** Urine, faeces.

**Contraindications:** Insulin-dependent (type 1) diabetes mellitus, diabetic ketoacidosis, diabetic precoma or coma, hypersensitivity to glimepiride or other sulphonylureas or sulfonamides, serious renal or hepatic dysfunction, dialysis patients.

**Precautions:** Regular monitoring of glucose levels in blood and urine. Milder or absent symptoms of hypoglycaemia, e.g. in patients with autonomic neuropathy or taking beta blockers, clonidine, reserpine, guanethidine or other sympatholytic drugs. Temporary change over to insulin in exceptional stress situations (e.g. trauma, surgery, infections with fever). Mild to moderate renal or hepatic impairment, obesity. Adrenocortical insufficiency. Monitor hepatic and haematological function. Elderly.

**Interactions:** Insulin, oral antidiabetics, ACE-inhibitors, allopurinol, anabolic steroids and male sex hormones, probenecid, quinolones, salicylates, sulfinpyrazone, sulfonamides, tetracyclines, tritoqualine, trofosfamide, acetazolamide, barbiturates, corticosteroids, diazoxide, diuretics, epinephrine and other sympathomimetic agents, glucagon, laxatives, nicotinic acid (in high doses), oestrogens, phenothiazines, phenytoin, rifampicin, thyroid hormones, H2-receptor antagonists, clonidine, reserpine, acute and chronic alcohol intake, NSAIDs, phenylbutazone, anticoagulants, MAOIs, beta blockers, chloramphenicol, disopyramide, fibrates, azole antifungals, clarithromycin, cyclophosphamide, pentoxifylline, colessevelam.

**Adverse effects:** Hypoglycaemia, signs of adrenergic counterregulation, hepatitis, liver failure, thrombocytopenia, haemolytic anaemia, GI upset, skin reactions, blood dyscrasias, transient visual disturbances.

PharmaGuide (Prescribing Information) - UAE
- # X

**PharmaGuide** Search here...
 

Go to interaction Checker

Settings

Amarly Sanofi-aventis
 

Check Interactions

←
→

**Hypoglycaemic excluding Insulin**

**Sulphonylurea**

**Glimepiride**

**Tab 1 mg:** 2x15': AED 25

**Tab 2 mg:** 10': -

**Tab 2 mg:** 2x15': AED 44.5

**Tab 3 mg:** 10': -

**Tab 3 mg:** 2x15': AED 62.5

**Tab 4 mg:** 2x15': AED 75

**Risk Factor**

**Pregnancy:** Containdicated in pregnancy.

**Lactation:** Containdicated or not recommended.

**Contraindications:** Insulin-dependent (type 1) diabetes mellitus, diabetic ketoacidosis, diabetic precoma or coma, hypersensitivity to glimepiride or other sulphonylureas or sulfonamides, serious renal or hepatic dysfunction, dialysis patients.

**Precautions:** Regular monitoring of glucose levels in blood and urine. Milder or absent symptoms of hypoglycaemia, e.g. in patients with autonomic neuropathy or taking beta blockers, clonidine, reserpine, guanethidine or other sympatholytic drugs. Temporary change over to insulin in exceptional stress situations (e.g. trauma, surgery, infections with fever). Mild to moderate renal or hepatic impairment, obesity. Adrenocortical insufficiency. Monitor hepatic and haematological function, Elderly.

**Indications**

Non-insulin-dependent (type 2) diabetes mellitus.

**Dosage**

**Adults:** Usual initial dosage 1 mg once daily; daily dosage may be increased at intervals of 1-2 wk and carried out stepwise as follow: 1 mg, 2 mg, 3 mg, 4 mg, 6mg and inceptional cases 8 mg. Usual maintenace dose 1 mg to 4 mg daily.

**Children:** Not recommended.

**Alternatives for Amaryl** Sanofi-aventis

Glimepiride
Sulphonylurea
Hypoglycaemic excluding Insulin
Filter brands here..
Showing 22 alternatives for Amaryl with respect to Glimepiride.
<b>Adglim</b> Neobiocon
<b>Diameril</b> Pharmalines
<b>Diapride</b> Dar Al Dawaa
<b>Econid</b> Abbott
<b>Emipride</b> Global Pharma
<b>G Pride</b> Oman Pharma
<b>GLIMELIFE</b> LIFEPHARMA
<b>Gedimadel</b> Jedco
<b>Glide</b> Deef

## Specimen of information when you search any Generic Name (and/or Contents).

Scroll down the screen to see complete information.

---

### Ceftriaxone

**Cephalosporin** Inj 250 mg; 500 mg; 1 gm; 2 gm.

#### RISK FACTOR

**Pregnancy:** No evidence of risk in humans.

**Lactation:** Caution advised or effect undetermined.

**Indications:** Severe respiratory and genitourinary tract, bone and joint, abdominal infections, sepsis, meningitis.

**Dosage: Adults:** Usually 1 gm daily by deep IM, slow IV inj over at least 2-4 min, or IV infusion. Severe infections, 2-4 gm as a single dose every 24 hr. **Children:** Usually 20-50 mg/kg once daily by IM inj, slow IV inj over at least 2-4 min, or IV infusion. Severe infections, up to max 80 mg/kg daily (max 50 mg/kg in neonates). Doses over 50 mg/kg to be given by slow IV infusion over at least 30 min.

Peri-op prophylaxis: **Adults:** 1 gm as single IM or slow IV dose.

Colorectal surgery: **Adults:** 2 gm by IM, slow IV inj or infusion with anaerobic antibacterial.

Lower Respiratory Infection: **Adults:** IM/IV: Usual: 1-2 gm once daily (or in equally two divided doses). Max: 4 gm/day.

Otitis Media: **Children:** 50 mg/kg IM single dose. Max: 1 gm/dose.

Bone Infection: **Adults:** IM/IV: Usual: 1-2 gm once daily (or in equally divided two doses). Max: 4 gm/day.

Meningitis: IV: **Adults:** 1-2 gm once daily (or in equally divided two doses). Max: 4 gm/day. **Children:** Initial of 100 mg/kg (not to exceed 4 gm), then 100 mg/kg once daily or (in equally divided two doses) for 7-14 days. Max: 4 gm/day.

Septicaemia: IV: **Adults:** 1-2 gm once daily (or in equally divided two doses). Max: 4 gm/day. **Children:** 50-75 mg/kg in divided doses every 12 hr. Max: 2 gm/day.

Urinary Tract Infection: **Adults:** IM/IV: 1-2 gm once daily (or in equally divided two doses). Max: 4 gm/day.

Gonorrhoea: Single dose of 250 mg by IM inj.

**Advice to Patient:** This medication is to be administered by injection or infusion only.

**Contact** prescriber if there is burning/swelling/redness/pain at injection or infusion site or if there is rash, hives, itching, difficulty in breathing or if there is swallowing, severe unrelieved diarrhoea, vaginal drainage or itching, mouth sores, blood, pus or mucus in stool or urine, easy bruising or bleeding, unusual chills or fever.

**Watery** or bloody stools can occur 2 or more months after therapy and can be serious, requiring immediate treatment.

**Take** sufficient amount of fluids (2-3 litres per day) to maintain hydration, unless restricted by the prescriber.

**Administration:** Ceftriaxone may be administered by IV intermittent infusion over 10-30 min; final concentration for IV administration should not exceed 40 mg/mL.

The drug has also been administered by direct IV push over 2-4 min. Inject deep IM into large muscle mass.

**IM Injection:** 250 mg/500 mg/1000 mg VIAL: To make concentration of 250 mg/mL add Water for Injection 0.9 mL in 250 mg vial; 1.8 mL in 500 mg vial; 3.6 mL in 1000 mg vial.

**IV:** 250 mg/500 mg/1000 mg VIAL: To make concentration of 100 mg/mL add Water for Injection 2.4 mL in 250 mg vial; 4.8 mL in 500 mg vial; 9.6 mL in 1000 mg vial.

**Compatibility:** Stable in D5W with KCl 10 mEq, D5W, D10W, NS, mannitol 5%, mannitol 10%, sodium bicarbonate 5%, bacteriostatic water, SWFI.

**Y-site administration:**

*Drug to Drug IV Compatibility:* Acyclovir, amikacin, amiodarone, aztreonam, bumetanide, cephazolin, cisatracurium, dexamethasone, diltiazem, dopamine, enalapril, epinephrine, esmolol, fentanyl, furosemide, heparin, hydrocortisone, hydromorphone, insulin regular, lansoprazole, levofloxacin, lorazepam, methylprednisolone, metoclopramide, metronidazole, midazolam, morphine, nitroglycerin, nitroprusside, norepinephrine, pantoprazole, phenylephrine, propofol, vasopressin.

*Drug to Drug IV Incompatibility:* Alatrofloxacin, amphotericin B cholesteryl sulphate complex, amsacrine, azithromycin, calcium gluconate, diphenhydramine, dobutamine, filgrastim, fluconazole, imipenem, labetalol, magnesium sulphate, pentamidine, tobramycin, vinorelbine.

**When admixed:** Incompatible with aminophylline, clindamycin, linezolid, theophylline.

**Stability:** For IV infusion in NS or D5W, solution is stable for 24 hours at room temperature or 3 days when refrigerated.

**Pharmacokinetics:**

**Absorption:** IM: Well absorbed.

**Half-life elimination:** Neonates 1-4 days: 16 hrs. 9-30 days: 9 hrs. Children: 4.1-6.6 hrs. **Adults:** Normal renal and hepatic function: Approx. 5-9 hrs. Renal impairment (mild-to-severe): Approx. 12-16 hrs.

**Time to peak, serum:** IM: 2-3 hrs.

**Excretion:** Urine. Faeces.

**Contraindications:** Beta-lactam hypersensitivity. Premature newborns having less than 41 weeks postmenstrual age; neonates over 41 weeks postmenstrual age with jaundice, hypoalbuminaemia or acidosis; concomitant treatment with IV calcium (including total parenteral nutrition containing calcium) in neonates over 41 weeks postmenstrual age - risk of precipitation in urine and lung. Do not use in hyperbilirubinaemia neonates.

**Precautions:** Severe renal and hepatic impairment. Do not use in pregnancy unless absolutely indicated. Monitor FBC during prolonged treatment. Non-severe hypersensitivity to other B lactams.

**Interactions:** Oral contraceptives, calcium containing IV solns.

**Adverse effects:** GI upset, skin reactions, blood dyscrasias. Rarely pseudomembranous colitis, raised liver enzymes, glucosuria, oliguria, haematuria, bronchospasm, phlebitis at inj site, urinary and biliary precipitates, pancreatitis, nephrolithiasis, haemolytic anaemia, positive Coombs test.

PharmaGuide (Prescribing Information) - UAE

PharmaGuide Search here...

Ceftriaxone

**Cephalosporin**  
**Cephalosporin**  
**IM Inj 250 mg/500 mg/1 gm:** Ceftriaxone 250 mg/500 mg/1 gm (as sodium); powder in vial.  
**IV Inj 250 mg/500 mg/1 gm/2 gm:** Ceftriaxone 250 mg/500 mg/1 gm/2 gm (as sodium); powder in vial.

**Risk Factor**  
**Pregnancy:** No evidence of risk in humans.  
**Lactation:** Caution advised or effect undetermined.  
**Contraindications:** Beta-lactam hypersensitivity. Premature newborns having less than 41 weeks postmenstrual age; neonates over 41 weeks postmenstrual age with jaundice, hypoalbuminaemia or acidosis; concomitant treatment with IV calcium (including total parenteral nutrition containing calcium) in neonates over 41 weeks postmenstrual age - risk of precipitation in urine and lung. Do not use in hyperbilirubinaemia neonates.  
**Precautions:** Severe renal and hepatic impairment. Do not use in pregnancy unless absolutely indicated. Monitor FBC during prolonged treatment. Non-severe hypersensitivity to other B lactams.

**Indications:**  
 Severe respiratory and genitourinary tract, bone and joint, abdominal infections, sepsis, meningitis.

**Dosage:**  
**Adults:** Usually 1 gm daily by deep IM, slow IV inj over at least 2-4 min, or IV infusion. Severe infections, 2-4 gm as a single dose every 24 hr. **Children:** Usually 20-50 mg/kg once daily by IM inj, slow IV inj over at least 2-4 min, or IV infusion. Severe infections, up to max 80 mg/kg daily (max 50 mg/kg in neonates). Doses over 50 mg/kg to be given by slow IV infusion over at least 30 min.  
**Peri-op prophylaxis: Adults:** 1 gm as single IM or slow IV dose.  
**Colorectal surgery: Adults:** 2 gm by IM, slow IV inj or infusion with anaerobic antibacterial.  
**Lower Respiratory Infection: Adults:** IM/IV: Usual: 1-2 gm once daily (or in equally two divided doses). Max: 4 gm/day.  
**Otitis Media: Children:** 50 mg/kg IM single dose. Max: 1 gm/dose.  
**Bone Infection: Adults:** IM/IV: Usual: 1-2 gm once daily (or in equally divided two doses). Max: 4 gm/day.  
**Meningitis: IV: Adults:** 1-2 gm once daily (or in equally divided two doses). Max: 4 gm/day. **Children:** Initial of 100 mg/kg (not to exceed 4 gm), then 100 mg/kg once daily (or in equally divided two doses) for 7-14 days. Max: 4 gm/day.  
**Septicaemia: IV: Adults:** 1-2 gm once daily (or in equally divided two doses). Max: 4 gm/day. **Children:** 50-75 mg/kg in divided doses every 12 hr. Max: 2 gm/day.  
**Urinary Tract Infection: Adults:** IM/IV: 1-2 gm once daily (or in equally divided two doses). Max: 4 gm/day.  
 Gonorrhoea: Single dose of 250 mg by IM inj.

**Brands for Ceftriaxone**  
 Filter brands here...  
 Showing 22 brands for Ceftriaxone.

- Advacef Neopharma
- Axone Pharma International
- CEFLAB Labotec
- Cefbact Casidia
- Cefaxon Jazera
- Ceftra Lupin
- Ceftriaxone-Tabuk Tabuk Pharma
- Ceftriax Kspico
- Enoxirt Julphar
- Epicephin E.I.P.I.Co.
- Longacef United Pharma
- Medaxonium Medochemie
- Megion Novartis
- Mesporin Megpha
- Oframax Ranbaxy
- Rocephin Roche
- Roxcef A.P.M
- ROXONE Medochemie
- Rozaxon National Company

## Settings Menu

Click the settings icon to view the following screen.

PharmaGuide (Prescribing Information) - Country

PharmaGuide Search here...

**Settings**  
 epharmaguide@gmail.com


- Check for Updates **1**
- Select Data Set **2**
- Subscribe to Data **3**
- Help & Usage
- Visit [www.epharmaguide.com](http://www.epharmaguide.com)
- Reset **4**
- Exit
- Last Update Date: April 27, 2023
- Subscription Expiry Date: Dec 31, 2025

Select a drug from the search above to see its prescribing information.

- 1 Click to check and download updated data.
- 2 Click when you need to switch from one country to another country.
- 3 Click when you need to enter 14 digit subscription code.
- 4 If the app isn't working correctly, try resetting it by tapping "RESET APPLICATION" and logging in again with your email address. Only use this feature when necessary.

## How can users access data for any country where information is available?

Click on the settings option to view the following screen.



Select one country of your choice and the subscribed data of that country will appear on your computer. This can be done (changed or re-changed) as many times as you desire. No internet connection is required to use this feature.



**FAQ**  
**(Frequently Asked Questions)**

### **How many devices can simultaneously use PharmaGuide data using the same “14-digit” subscription code?**

PharmaGuide data cannot be simultaneously used on more than one device using the same “14-digit” subscription code. The prepaid “14-digit” subscription code is for one time use only. If the application is being used on more than one device using the same “14-digit” subscription code, the subscription will be automatically blocked.

### **Is PharmaGuide Desktop App subscription based?**

Yes, PharmaGuide Desktop App is subscription-based. The application is available with complete data only for subscribed users. To access the complete data, you need to purchase a prepaid 14-digit subscription code. The subscription is valid for one year, starting from the date of download. After one year, you will need to re-subscribe by purchasing a new prepaid 14-digit subscription code. This ensures that you always have access to the latest available medical information.

### **Why is my PharmaGuide Desktop App now displaying sample data when I have already entered the prepaid 14 digit subscription code?**

If your PharmaGuide Desktop App is displaying sample data even though you have entered the prepaid 14-digit subscription code, it is possible that your subscription has expired. The subscription is valid for one year, starting from the date of download. Once the subscription period has ended, the app will display sample data until you renew your subscription by purchasing a new 14-digit subscription code.

### **How can I get the 14-digit subscription code for PharmaGuide Desktop App?**

Please visit our website: <https://www.epharmaguide.com/shop> or contact our local office via phone or email at [support@epharmaguide.com](mailto:support@epharmaguide.com).

### **Which computer machines are supported by PharmaGuide Desktop App?**

PharmaGuide Desktop App supports personal computers that meet the following requirements:

- Microsoft Windows XP Service Pack 3 or later operating system versions
- Sufficient RAM and hard disk space to run the application smoothly

Please ensure that your computer meets these requirements before downloading and installing PharmaGuide Desktop App to ensure the best user experience.

### **Do I need to connect to the Internet to use PharmaGuide Desktop App?**

No, an internet connection is not required to use PharmaGuide Desktop App. It is an offline application. However, you need Internet access for about two to five minutes to download the data. Once downloaded, you can use the application without an internet connection.

### **How can I know when my subscription expires and whether my data is updated or not?**

To check your subscription expiry date and data update in PharmaGuide Desktop App, go to the "Settings" option on the top right corner of the screen. You can view your subscription expiry date and data update date from there.

### **How can I update my data?**

To update your data in PharmaGuide Desktop App, you need to connect to the Internet at least once every 30 days to receive automatic updates. Alternatively, you can go to the "Settings" option, connect to the Internet, and click on "Check for Updates" to manually update your data.

### **How do I know which country's data I am currently viewing?**

To know which country's data you are viewing in PharmaGuide Desktop App, check the top of the screen for the name of the respective country (e.g., UAE, Qatar, etc.).

### **Can I switch between countries to view the data of any other country?**

Yes, you can switch between countries to view the data of any other country in PharmaGuide Desktop App, as many times as you like. No internet connection is required as it is an offline application.

### **How do I switch to another country to see its data?**

Click on the settings option at the top right of the screen, and then click on 'Select Data Set.' You can then select the desired country from the drop-down menu.

### **My application is not working properly (e.g. search result is not appearing or showing some error). What should I do?**

To fix errors in the application, connect to the internet, click on the setting option, and select 'Reset Application' to restart the application. Now, login using your email address. This will start the application without any error. Please do not use this feature unless it is necessary. For further guidance, you can contact the support team by either calling the local office or sending an email to [support@epharmaguide.com](mailto:support@epharmaguide.com).

### **I have lost or forgot my email address. Do I have to purchase another subscription code?**

No, you do not need to make another subscription purchase if you have misplaced or forgotten your email address. It is important to provide accurate details in the subscription form during the download process. This will allow us to verify your personal information and retrieve your account information. If you require assistance with this, you can reach out to our local office or contact our support team at [support@epharmaguide.com](mailto:support@epharmaguide.com). Once we have successfully verified your account, you will be able to download the complete data again onto your computer at no extra charges.

## **PharmaGuide Editorial Policy, Source of Information and Liability of Information**

**Editorial information:** PharmaGuide is not a substitute for full prescribing information of any medicine. Medical and allied health professionals must be familiar with the full prescribing information of every product he/she prescribes or dispenses. PharmaGuide contains comprehensive information designed solely for use by medical and allied health professionals as a reminder of basic information such as indications, dosage and contraindications. The information has been deliberately kept concise in a standardized format so that it serves as a convenient, quick and easy reference tool. The training and experience of doctors is essential to forming any opinion on the appropriateness of a specific drug for any particular patient. In reaching professional judgment on whether to prescribe a product, which product to prescribe, and under what regimen, the doctor should thoroughly understand the options available for any clinical application, the potential effectiveness of each product, and the associated risks and side effects. This knowledge should be considered in light of the special circumstances of a patient, for each patient is unique. No single reference can substitute medical training and experience. The doctor must be familiar with the full product information of every product he or she prescribes, as well as the relevant medical information. The prescribing & dispensing decisions are ultimately the responsibility of members of the healthcare profession. PharmaGuide is offered to assist medical and allied health professionals in this area and minimize medication errors. **Drug Interaction Checker** is an add-on to the PharmaGuide Application. Information of Drug Interaction is also provided in the prescribing information section of products. Drug Interaction Checker includes only those interactions for which specific drug interaction studies demonstrating severity, onset, effects, mechanism and management have been published. Some drug interactions are not included in the Drug Interaction Checker because specific studies covering all the above parameters have not been published. Users are therefore advised to refer to INTERACTIONS in the prescribing information section of this application in order to determine whether or not drug interaction exists.

**Source of Information:** All products are classified in the Therapeutic Category according to the Anatomical Therapeutic Classification (ATC) Table of EphMRA (European Pharmaceutical Market Research Association, a non-profit organization for the classification of all pharmaceutical products in the world). They have developed and maintained a classification system that clearly mentions which products are to appear under which Pharmacological Therapeutic Category. This list is similar to that of WHO Anatomical Therapeutic Classification. Both the organizations EphMRA and WHO are

continuously working together for unification of classification of codes of pharmaceutical products. PharmaGuide strictly adheres to EphMRA Classification and accordingly, all the pharmaceuticals are placed in their relevant Therapeutic Categories. The sources for prescribing information of medicines are USFDA and UKMOH full prescribing information of medicines, which are approved by USFDA and UKMOH. The sources also include full prescribing information of products provided by the manufacturers to the medical and allied health profession, if supported by USFDA or UKMOH. These are the sources of information for prescribing information i.e. indications, dosage, administration, contraindications, precautions, drug-drug interactions and adverse effects. Cross validation of information is also done from the information provided in world- recognized textbooks and reference books on pharmacology and therapeutics, for example, Martindale The Extra Pharmacopeia, Good & Gillman's The Pharmacological Basis of Therapeutics and Drug Facts & Comparisons USA.

**Liability of Information:** PharmaGuide has more than three decades of experience in disseminating prescribing information. It is not an official compendium or reference book of any ministry of health, neither a substitute for an official compendium. PharmaGuide is a quick reference source of information, to be referred only by medical and allied health professionals, to assist them in fulfilling their professional responsibilities. PharmaGuide takes full liability if any wrong or misleading prescribing information is provided in the publication, to the extent that if the information does not appear in the USFDA and UKMOH full prescribing information or world-recognized text books and reference books on pharmacology and therapeutics. At any point of time PharmaGuide can provide the specific source for any specific pharmaceutical product information on demand. Every effort has been made to make the information accurate and error- free. However, chances of minor human error may be possible keeping in view that data is collected, compiled and standardized from different countries. Therefore, PharmaGuide, its employees or agents cannot be held responsible for any human error or omission howsoever, or for any consequence arising therefrom.

*All rights reserved. No part of this publication may be reproduced, stored at a retrieval system, or transmitted in any form or by any means- electronic, mechanical, photocopying, recording or otherwise without the prior written permission of **PharmaGuide** Systems management.*